Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Step Therapy Metastatic Cancer topic
No spam. Unsubscribe anytime.
Advocates press committee to add 'associated conditions' to metastatic cancer step‑therapy rules (SB 2248)
Summary
Susan G. Komen and other advocates urged the Senate Human Services Committee to amend step‑therapy law to include side effects and symptoms of metastatic cancer as ‘‘associated conditions’’ exempt from fail‑first protocols. Supporters said timely access for metastatic patients is crucial; business groups cautioned that adding mandates can raise
The Senate Human Services Committee heard testimony on Senate Bill 2248, which would amend the state’s step‑therapy statute to add ‘‘associated conditions’’—symptoms and side effects arising from metastatic cancer or its treatments—so those conditions would be treated as grounds for exceptions to fail‑first step‑therapy rules.
Bobby Will, representing Susan G. Komen, told senators that side effects such as nausea, low white blood count, diarrhea, depression and pain are common in metastatic cancer care and that physicians should be able to prescribe treatments to prevent or manage those effects without insurers requiring a patient to first fail on other therapies. Will described the administration burden and the hardship experienced by patients and caregivers during delays.
Support and opposition: Patient advocates and clinical groups urged the committee to add metastatic associated conditions so clinicians can manage side effects promptly. The Greater North Dakota Chamber opposed portions of the bill (section 2) because they worry mandated benefit changes increase employer health‑insurance costs; the chamber also noted the bill lacked a fiscal note. Neutral testimony from the Public Employees Retirement System’s executive director reported the PERS actuary estimated no fiscal impact to the PERS plan in its current form because the carrier already covers the treatments in question.
Why it matters: Supporters said metastatic cancer patients often need rapid, individualized care to maintain quality of life during advanced illness, and they argued existing step‑therapy requirements can produce harmful delays. Opponents warned about cumulative cost impacts from mandates on small‑group employer plans.
Outcome: The committee closed testimony on SB 2248; no committee vote was recorded in the hearing transcript.
